Equities

Modulight Oyj

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Modulight Oyj

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.08
  • Today's Change-0.032 / -2.87%
  • Shares traded23.26k
  • 1 Year change-23.80%
  • Beta1.8810
Data delayed at least 15 minutes, as of Mar 02 2026 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Modulight Oyj is a Finland-based technology company that designs, markets and manufactures laser products, including semiconductors, laser modules, complete cloud connected laser systems and related software and analytics services for demanding medical technology and technology companies and target markets around the world. Modulight provides biomedical lasers for medical applications, including oncology, ophthalmology and genetics, as well as other diagnostics for medical and biomedical segments. Additionally, the Company offers customized biomedical laser solutions, including wavelength, optical power and laser output beam engineering enabled by its own fabrication plant and semiconductor process. Modulight Oyj is the Group's Parent Company. The Company’s subsidiaries include Modulight China Export A Oy, Leaptek Photonics Oy, and Modulight USA Inc.

  • Revenue in EUR (TTM)7.07m
  • Net income in EUR-4.60m
  • Incorporated2000
  • Employees71.00
  • Location
    Modulight OyjHermiankatu 22TAMPERE 33720FinlandFIN
  • Phone+358 207439000
  • Fax+358 333991210
  • Websitehttps://modulight.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
INIFY Laboratories AB1.89m-5.76m28.87m34.00--2.35--15.29-1.13-1.130.36641.700.19282.963.12848,737.60-58.78---58.78--85.20---304.93------0.00--1,000.67--3.15------
Acarix AB689.95k-4.51m29.91m8.00--8.67--43.35-0.0427-0.04270.00650.03280.1140.16583.37---74.50-80.03-84.46-94.1984.7483.62-653.38-1,091.793.45-623.52----18.6927.6727.34------
Ortoma AB7.24m-704.81k39.01m10.00--2.6479.705.39-0.2027-0.20272.084.450.42433.9539.137,530,537.00-4.13-9.37-4.45-10.4341.26158.24-9.74-78.903.02--0.00--28.77--46.83---0.5751--
Mentice AB25.73m-4.06m40.47m121.00--3.43--1.57-1.68-1.6810.524.480.96631.603.942,095,328.00-15.25-6.64-31.60-11.9190.4084.80-15.78-8.530.845-30.100.116--6.1114.22-553.89--32.86--
Q linea AB1.04m-17.11m43.66m83.00--1.38--41.97-35.87-35.871.3117.840.04290.40062.90---70.50-76.00-101.81-93.84-15.26-145.47-1,644.30-2,820.5110.04-30.480.017--369.86114.7515.86---34.47--
Modulight Oyj7.07m-4.60m47.48m71.00--1.06--6.72-0.12-0.120.18741.050.1341-1.014.54---8.73-11.40-9.39-12.14132.06125.90-65.10-126.563.79--0.0588--72.63-6.8228.59--15.83--
Bactiguard Holding AB21.45m-735.32k50.64m153.00--1.9413.772.36-0.2238-0.22386.538.990.3813.446.911,495,216.00-1.31-8.02-1.86-10.1363.7848.56-3.43-25.101.38-0.33870.3410---12.644.2273.69---17.92--
Gentian Diagnostics ASA15.71m1.18m54.21m63.0046.702.9727.233.450.84590.845911.3513.290.72311.566.36--5.43-0.04836.25-0.05555.6447.277.51-0.07883.81--0.0866--16.0722.75-70.73--10.72--
Optomed Oyj17.10m-6.64m57.39m111.00--2.39--3.36-0.3374-0.33740.86881.120.53632.875.07154,009.00-20.83-17.19-25.75-20.6963.6064.81-38.85-34.212.03-8.910.1014--13.675.61-21.83--5.30--
BioPorto A/S4.89m-11.62m59.97m48.00--11.70--12.26-0.1973-0.19730.0830.07740.41322.554.69962,131.60-98.08-65.22-133.92-88.7463.9064.15-237.40-222.221.71--0.1916--17.076.36-21.15---20.56--
Nanexa AB3.39m-1.07m61.48m15.00--6.39570.3218.14-0.0724-0.07240.22550.62370.314416.225.232,409,933.00-9.90-31.63-12.96-38.7886.0296.94-31.50-218.011.51-3.210.0109--48.3972.5054.27--3.54--
Senzime AB (publ)9.75m-12.88m66.32m50.00--2.32--6.80-0.9396-0.93960.70731.940.26192.617.48---34.60-36.25-37.96-39.0233.3524.11-132.11-271.043.04-7.450.044--77.8961.95-15.74--123.16--
OssDsign AB16.89m-4.78m67.10m32.00--2.31--3.97-0.5493-0.54932.062.800.51090.36726.955,629,938.00-14.46-25.42-16.05-28.5996.2985.57-28.30-82.426.33-13.770.0044--34.5148.59-2.68--24.28--
Data as of Mar 02 2026. Currency figures normalised to Modulight Oyj's reporting currency: Euro EUR

Institutional shareholders

10.85%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 27 Mar 20253.28m7.69%
Didner & Gerge Fonder ABas of 31 Dec 2024670.32k1.57%
Protean Funds Scandinavia ABas of 28 Feb 2025393.39k0.92%
Keskin�inen Vakuutusyhti� Kalevaas of 27 Mar 2025149.96k0.35%
Aktia Asset Management Ltd.as of 31 Dec 2024133.78k0.31%
More ▼
Data from 30 Nov 2025 - 02 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.